J&J buys into spine test firm
This article was originally published in The Gray Sheet
Johnson & Johnson leads a $15.3 million financing round and enters a strategic collaboration with Axial Biotech to accelerate the start-up's development of a genetic test to pre-symptomatically predict which cases of scoliosis, or abnormal curvature of the spine, are likely to progress and require intervention, firms announce March 27. Axial hopes to launch the first-of-its-kind test in late 2008, and estimates a U.S. market size of $180 million. The Raynham, Mass. firm also is developing minimally invasive devices for spine surgery...
You may also be interested in...
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Among the largest gaps in safety data is non-clinical research on CBD use's effect on developing fetus and adolescent brain, in utero/lactational exposure, reproductive toxicity and the potential for a latency period before toxicity, says FDA neuroscientist Andrew Shen.
The templates from the US agency provide guidance to manufacturers developing antibody tests for clinical or at-home use.